Preemptive antiviral therapy is often employed for CMV prevention following allogeneic BMT. Two common strategies are a screening bronchoscopy for CMV post-BMT or regular CMV antigenemia testing with ganciclovir administration for a positive result. In a randomised trial, we prospectively compared the efficacy of these two preemptive strategies. Consecutive patients were randomised to either a bronchoscopy for CMV on day 35 post BMT or weekly CMV antigenemia testing. If the bronchoscopy was positive for CMV, patients received preemptive ganciclovir for 8-10 weeks. If the antigenemia was positive for CMV, patients received a minimum of 2 weeks of preemptive ganciclovir. The primary endpoint was the development of active CMV disease. One hundred and eighteen allogeneic BMT patients were enrolled (60 in the antigenemia arm and 58 in the bronchoscopy arm). The two groups were comparable with respect to baseline demographic data, underlying disease, conditioning regimen, and immunosuppression. Active CMV disease developed in 7/58 (12.1%) patients in the bronchoscopy arm vs 1/60 patients (1.7%) in the CMV antigenemia arm (P = 0.022). Based on the screening test, 13.8% of patients received preemptive ganciclovir in the bronchoscopy arm vs 48.3% of patients in the antigenemia arm (P Ͻ 0.001). There was no significant difference in the rate of graft-versus-host disease, bacteremia, invasive fungal infections or mortality between the two groups. Preemptive therapy based on regular CMV antigenemia monitoring is superior to screening bronchoscopy for the prevention of CMV disease after allogeneic BMT. Bone Marrow Transplantation ( Keywords: cytomegalovirus; preemptive therapy; antigenemia; bronchoscopy; bronchoalveolar lavage Two commonly employed strategies to prevent cytomegalovirus (CMV) disease after allogeneic bone marrow transplantation (BMT) are universal prophylaxis and preemptive therapy.
Two commonly employed strategies to prevent cytomegalovirus (CMV) disease after allogeneic bone marrow transplantation (BMT) are universal prophylaxis and preemptive therapy. 1, 2 Universal prophylaxis involves the administration of antiviral therapy to all at-risk patients. Administration of intravenous ganciclovir until day 100 post BMT to all at-risk patients is a form of universal prophylaxis that has been demonstrated to be effective in the prevention of CMV disease. 3, 4 However, a significant rate of late CMV disease occurring after discontinuation of ganciclovir prophylaxis has been observed. 5 In addition, an increased rate of bacteremia and invasive fungal infection, possibly due to ganciclovir-induced neutropenia, has been noted in some studies. 3, 4, 6 With preemptive therapy, patients are monitored using one or more laboratory tests to detect early evidence of CMV infection. Patients with CMV infection are then treated with antiviral therapy in order to prevent the development of symptomatic CMV disease. In addition to targeting only patients at high risk of developing CMV disease, a preemptive strategy may allow patients to develop CMV-specific cytotoxic T cell immunity thereby decreasing the likelihood of late onset CMV disease as seen with universal prophylaxis protocols. A strategy utilizing a day 35 post-BMT screening bronchoscopy in which preemptive ganciclovir is administered to all patients with a positive CMV culture of bronchoalveolar lavage (BAL) fluid, has been shown to decrease the incidence of active CMV disease. 7, 8 However, this method is invasive, costly, may be associated with adverse effects related to bronchoscopy, and generally allows for only one or two determinations of CMV reactivation post BMT. In addition, a significant proportion of patients with a negative screening bronchoscopy still develop active CMV disease. 7 Numerous other diagnostic tests for the early detection of CMV are currently available and include blood, urine, and throat cultures, the CMV antigenemia assay as well as molecular diagnostic assays such as PCR and hybridization assays. [9] [10] [11] The minimally invasive nature of such tests allows for multiple determinations over a period of time post BMT to monitor for CMV reactivation. Therefore, patients with a positive screening test may be treated with short-course preemptive ganciclovir with ongoing screening for CMV, and repeat antiviral therapy for patients with a CMV recurrence. We compared the efficacy of two preemptive strategies, the first utilizing a day 35 screening bronchoscopy, and the second using weekly antigenemia assays for the prevention of CMV disease following allogeneic BMT. These strategies differ not only in the laboratory test used to guide preemptive therapy, but also the subsequent duration of antiviral therapy employed in patients with a positive screening test.
Methods

Patient population
The protocol received ethics approval by the institutional review board. Between April 1998 and April 2000, adult patients receiving allogeneic BMT or allogeneic peripheral blood stem cell transplantation at the Princess Margaret Hospital, Toronto, Canada were eligible for enrollment if they were seropositive for CMV pre-transplant and/or received a transplant from a CMV seropositive donor. Written informed consent was obtained from all patients. Patients who declined study received what was then our standard day 35 bronchoscopy.
Study design
The study was powered to detect a significant reduction (20%) in the combined endpoint of CMV disease and mortality in the antigenemia arm (alpha of 0.05 and a power of 80% with a one-sided test). Patients were enrolled into the study prior to transplantation. Following enrollment, patients were randomised to either the day 35 screening bronchoscopy arm (BAL) or the antigenemia arm. Randomisation was performed on day 20 post transplant to ensure that patients were randomised as close as possible to the intervention and to avoid the issue related to early deaths post transplant which are not CMV related. Patients were followed for a minimum of 6 months post transplant or until death.
Patients in the screening bronchoscopy arm underwent a day 35 bronchoscopy for CMV culture of BAL fluid. Patients with a negative BAL had no intervention and were followed clinically with appropriate testing done for CMV (such as CMV antigenemia, diagnostic bronchoscopy with shell vial culture and cytology) if any signs or symptoms suggestive of active CMV disease developed. Patients with a positive BAL received 2 weeks of induction therapy with intravenous ganciclovir (5 mg/kg twice a day) followed by an 8-week maintenance course of ganciclovir (5 mg/kg once daily 5 days/week).
Patients randomised to the antigenemia arm had weekly CMV antigenemia measurements starting from day 21 until day 120 post BMT. Patients with negative antigenemia results had no intervention and were followed clinically. Patients with a positive antigenemia test received preemptive intravenous ganciclovir therapy (5 mg/kg twice daily) for a minimum of 2 weeks or until the antigenemia became negative. Following the 2-week course, ganciclovir was discontinued and weekly monitoring resumed until day 120. All relapses in CMV antigenemia were treated in a similar manner.
Active CMV disease was defined according to standard clinical criteria. 12 Specifically, CMV pneumonitis was diagnosed in a patient with characteristic signs and symptoms, with a chest radiograph demonstrating interstitial infiltrates and a BAL or lung biopsy positive for CMV with no other etiology found. Other end-organ disease was diagnosed by biopsy or a compatible clinical picture with culture or PCR evidence of CMV and no other etiology found. Due to logistic and ethical reasons, patients and treating physicians were not blinded to the assigned study arm. However, whenever possible, study personnel assessing specific outcomes such as the development of CMV disease were blinded as to which strategy the patient was randomised to receive.
Laboratory procedures
Pre-transplant recipient and donor CMV serology were determined using the Abbott AxSYM enzyme immunoassay (Abbott Laboratories Ltd, Abbott Park, IL, USA). Shell vial cultures of BAL fluid and the CMV antigenemia assay were performed using methods previously described. 13, 14 An antigenemia level of у1 positive cell per slide (100 000 cells/slide) was considered a positive result.
Statistical analysis
The primary endpoint was CMV disease at latest followup. The occurrence of CMV disease and overall mortality were compared using a log rank test from a Kaplan-Meier survival analysis. Other categorical variables were compared using a corrected chi-square or Fisher's exact test. Continuous variables were compared using a Student's ttest or a Mann-Whitney U test. All statistical analysis was done using SPSS version 9.0 (Chicago, IL, USA).
Results
Study population
During the 2-year patient enrollment period from April 1998 to April 2000, 230 allogeneic BMTs were preformed. Of these, 68 were CMV seronegative and received a transplant from a CMV seronegative donor and were therefore ineligible for the study. Of the 162 patients eligible for enrollment, 37 refused consent and the remaining 125 were enrolled in the trial. Of these, six died prior to randomisation (day 20 post transplant) and one patient withdrew after randomisation leaving 118 study patients (58 in the bronchoscopy arm and 60 in the antigenemia arm). Baseline characteristics of both groups are shown in Table 1 . No significant differences were present in terms of demo- graphic characteristics, underlying disease, conditioning regimen, and degree of HLA match between the two arms of the study (Table 1) . Median follow-up for surviving patients was 486 days (range 229-864 days).
CMV disease
CMV disease rates in the two arms are shown in Figure 1 and Table 2 . In the antigenemia screening arm of the study, In the BAL arm of the study, of the seven patients with CMV disease, six developed CMV pneumonitis, and one patient had hemorrhagic cystitis. The latter patient had compatible symptoms, with a positive urine culture for CMV, positive blood antigenemia assay, negative culture and/or electron microscopy for adenovirus and polyomavirus and a prompt response to ganciclovir.
Patients with CMV disease in this arm of the study presented a mean of 62.2 days post transplant (median 54 days; range 37-119 days).
Screening CMV antigenemia
Of the 60 patients in the antigenemia arm of the study, 29 (48.3%) had at least one positive screening antigenemia and therefore received preemptive ganciclovir. Antigenemia became positive a mean of 52. 
Day 35 BAL
Of the 58 patients randomised to the day 35 screening bronchoscopy, eight patients (13.8%) had a positive result and received preemptive ganciclovir. Patients received a mean of 6.4 weeks of ganciclovir (median 7 weeks; range 1-10 weeks). One patient died prior to completing preemptive ganciclovir, and therapy was discontinued early in an additional three patients due to the development of leukopenia. Two patients died prior to the day 35 bronchoscopy, and one patient did not receive a day 35 bronchoscopy due to concurrent illness and was followed using serial antigenemia assays. This patient did not develop CMV disease and was analyzed in an intent-to-treat fashion in the BAL arm.
Protocol violations
Protocol violations were documented when patients received preemptive or prophylactic ganciclovir for criteria other than those defined by the study. A total of seven protocol violations occurred. All seven of these patients were randomised to the BAL arm but had an antigenemia assay ordered by the treating physician at some point during their post-transplant course. Antigenemia assays were ordered for non-specific indications such as leukopenia or thrombocytopenia, in patients who did not meet strict criteria for CMV disease. Antigenemia in these seven patients ranged from two to 100 positive cells per slide. Patients received between 2 and 4 weeks of preemptive intravenous ganciclovir. Only one of these patients eventually developed CMV disease by strict diagnostic criteria. The remaining patients were analyzed in an intention-to-treat manner and were therefore counted as successful CMV disease prevention in the BAL arm.
Other outcomes
With the exception of CMV disease, there was no effect of different preventative strategies on other outcomes ( Table 2 ). The incidence of fungal infection and bacteremia was the same in both arms of the study. There was also no difference in overall mortality between the two groups. Significant ganciclovir-induced neutropenia (sufficient to result in G-CSF administration) occurred in five (8.6%) patients in the BAL arm and seven (11.7%) patients in the antigenemia arm (P = NS). Significant GVHD (grade 2-4) occurred at a similar rate in the two arms ( Table 2 ). The total number of patients receiving ganciclovir (including preemptive therapy, protocol violations, and treatment of CMV disease) was not statistically different in the two arms (20/58 (34.5%) BAL arm vs 30/60 (50.0%) in the antigenemia arm; P = 0.13).
Discussion
In this randomised controlled trial we compared two different preemptive strategies, the first based on a day 35 screening bronchoscopy and the second based on sequential antigenemia testing, for their effectiveness in preventing CMV disease in allogeneic BMT recipients. In the 118 patients randomised, 7/58 (12.1%) patients in the BAL arm developed CMV disease compared with only 1/60 (1.7%) in the antigenemia arm (P = 0.022). Based on the screening test result, 48.3% of patients in the antigenemia arm received preemptive ganciclovir compared with 13.8% in the BAL arm (P Ͻ 0.001). However, when treatment of CMV disease and protocol violations in the BAL arm were included, the number of patients eventually receiving ganciclovir therapy was not significantly different in the two arms. The incidence of significant ganciclovir-induced neutropenia (requiring G-CSF) was similar in both groups and no difference in the incidence of bacteremia or invasive fungal infections occurred. No difference in overall mortality was demonstrable. It should be emphasised that these strategies differed not only in the laboratory test used for screening patients, but also the duration of subsequent preemptive ganciclovir. Since antigenemia testing may be repeated at regular intervals, we used a much shorter course of preemptive therapy in this arm (2 weeks) compared to the bronchoscopy arm (10 weeks). Two approaches to CMV prevention after allogeneic BMT are generally utilized: universal prophylaxis and preemptive therapy. Goodrich et al 3 evaluated universal ganciclovir prophylaxis in 64 patients randomised to placebo or intravenous ganciclovir for 100 days. CMV disease occurred in 0/33 patients receiving ganciclovir compared with 9/31 (29%) with placebo (P Ͻ 0.001). Although an additional three patients (9%) developed CMV disease after ganciclovir discontinuation, this was still superior to the placebo group. However, the authors did note an increased risk of bacteremia associated with ganciclovir-induced neutropenia. In another placebo controlled trial, Winston et al 4 also demonstrated a significant reduction in CMV disease with the use of universal ganciclovir prophylaxis although longer follow-up results were not provided. However, late CMV pneumonitis has been observed as a problem in patients receiving prolonged universal ganciclovir prophylaxis. In a cohort of 541 BMT patients treated with 3 months of ganciclovir prophylaxis, CMV pneumonitis occurred in 6.3% (34/541) of patients but developed at a mean of 188 days post transplant with 74% of episodes occurring after day 100. 5 The second approach to CMV prevention is preemptive therapy. Since patients in a preemptive strategy do not receive antiviral therapy until the development of CMV infection, patients may have the opportunity to develop specific anti-CMV cytotoxic T cell immunity, a process that may be delayed by universal ganciclovir prophylaxis. 15 Therefore, preemptive therapy has the potential for minimizing the occurrence of late CMV disease. Preemptive therapy also has the advantage of targeting only patients at the 489 highest risk of CMV disease to receive antiviral therapy thereby minimising potential adverse effects. Laboratory tests available for use in a preemptive strategy include culture-based methods (BAL fluid, blood), the CMV antigenemia assay, and PCR or other molecular-based tests. [9] [10] [11] [16] [17] [18] A preemptive strategy using a day 35 screening bronchoscopy followed by ganciclovir therapy for patients with a positive CMV culture was prospectively evaluated by Schmidt et al. 7 Compared with no therapy, the use of preemptive ganciclovir resulted in a significant reduction in CMV disease. However, active CMV disease still developed in 21% of the patients who had a negative screening bronchoscopy. 7 Using a similar strategy, we previously reported the successful use of a surveillance bronchoscopy followed by prolonged preemptive ganciclovir therapy. 8 Preemptive therapy guided by serial antigenemia testing has been compared with universal ganciclovir prophylaxis for 100 days. 10 CMV disease developed in 16/114 (14.1%) patients in the preemptive antigenemia arm compared with only 3/112 (2.7%) in the universal ganciclovir prophylaxis group. However, because an additional 15 patients developed CMV disease after the discontinuation of universal prophylaxis, the rate of disease was not significantly different by day 180 between the two groups. In addition, universal ganciclovir was associated with an increase in invasive fungal infections. The high rate of disease in the antigenemia arm observed in that study may have been because preemptive ganciclovir was only given to patients with high grade antigenemia (у3 positive cells/slide) while those with low level antigenemia were clinically observed. 10 In our study, we used a positive antigenemia result of у1 positive cell/slide to initiate preemptive therapy. Of the 29 patients who received preemptive ganciclovir in the antigenemia arm of our study, 12 patients (41%) had a first positive antigenemia of less than three cells.
Einsele et al 11 compared preemptive therapy guided by PCR vs preemptive therapy guided by blood culture surveillance for CMV. The rate of disease was 2/37 in the PCR group compared with 8/34 in the culture-based group and the authors were able to demonstrate a reduction in CMVassociated mortality with the use of PCR-based preemptive therapy. The rate of CMV disease observed with the use of PCR was similar to the rate we observed in the antigenemia arm of our study. However, to date, no randomised controlled trials comparing preemptive therapy guided by antigenemia vs PCR have been published.
One of the limitations of our study was that the physician and patients were not blinded as to the treatment arm. This was because of ethical and logistic reasons that precluded performing bronchoscopy in patients not randomised to this arm and which prevented the administration of prolonged courses of intravenous placebo ganciclovir. However, to minimize potential bias, research personnel assessing the outcome of CMV disease were blinded as to the randomisation arm whenever possible. Another limitation of our study was the occurrence of several protocol violations in patients randomised to the BAL arm. In these seven patients, a CMV antigenemia assay was performed, and patients were treated with ganciclovir for clinical or laboratory findings which did not meet strict criteria for CMV disease (usually leukopenia or thrombocytopenia). However, these protocol violations minimise the potential difference between the two arms since if ganciclovir therapy was not inadvertently used in the screening bronchoscopy patients, further cases of CMV disease may have occurred in this arm.
In summary, we demonstrate in a randomised controlled trial that a preemptive strategy utilising sequential antigenemia testing is superior to one in which patients undergo a screening bronchoscopy for the prevention of CMV disease. Significantly more patients in the antigenemia arm received preemptive ganciclovir. However, since antigenemia can be monitored at multiple time points after transplant, this strategy lends itself to shorter courses of ganciclovir with repeat administration for patients with recurrences. Other laboratory assays for the detection of CMV in blood such as molecular-based diagnostic tests including PCR-based methods should be compared in similar preemptive strategies. Future studies evaluating preemptive strategies should focus on determining which test is the best, what the optimal duration of antiviral therapy is, as well as determining the relative cost-effectiveness of various CMV prevention protocols.
